Alice Soragni

This paper develops a bioprinted organoid platform to evaluate multimodal therapies for HNSCC, showing differential responses to radiosensitizers in patient-derived models.

This study uses patient-derived organoids to model pheochromocytomas and paragangliomas, revealing hypoxia-driven plasticity and therapeutic vulnerabilities, including responses to abemaciclib.

This study identifies SUMO2 as a selective vulnerability in synovial sarcoma, showing that SUMO2 inhibition reverses SS18-SSX-driven gene expression and impairs tumor growth.

This study shows that mutant p53 aggregation occurs during malignant transformation in high-grade serous ovarian carcinoma and is absent in preneoplastic lesions.

This paper introduces a platform for establishing and screening patient-derived cutaneous neurofibroma organoids to support drug discovery for NF1-associated tumors.